Organization
Caris Life Sciences Research and Development
11 abstracts
Abstract
Kinome reprogramming as a therapeutic opportunity in ESR1 fusion driven breast cancer but not in gynecologic cancers.Org: Caris Life Sciences Research and Development, Tempero Bio, Azidus Brasil, Caris Life Sciences, Phoenix Tissue Repair,
Abstract
Therapeutic strategy for targeting recurrent oncogenic kinase gene fusions in prostate cancer.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX,
Abstract
The genomic, transcriptomic, and immunological profile of patients with recurrent/refractory NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX,
Abstract
Metabolic profile and therapeutic vulnerabilities of multi-omic characterization of KRAS/STK11/KEAP1 co-mutant non–small cell lung cancer (NSCLC).Org: Caris Life Sciences, Irving, TX, Penn State Milton S. Hershey Medical Center, Hershey, PA, Caris Life Sciences Research and Development, Montefiore Einstein Comprehensive Cancer Center/Albert Einstein College of Medicine,
Abstract
NRG1 fusions in solid tumors.Org: Caris Life Sciences, Irving, TX, Caris Life Sciences Research and Development, West Cancer Center and Research Institute,
Abstract
High transferrin receptor expression marks tumors with increased immune-effector infiltration and expression of targetable checkpoint molecules: Results of a multi-cancer analysis in solid tumors.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, City of Hope National Medical Center, St. John's Cancer Institute, Santa Monica, CA, Karmanos Cancer Institute,
Abstract
Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC).Org: Caris Life Sciences Research and Development, Emory University School of Medicine, University Of California San Diego Ideka Laboratory, Caris Life Sciences, Irving, TX, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care, Lombardi Comprehensive Cancer Center, Georgetown University, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK,
Abstract
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Department of Molecular Pharmacology and Therapeutics,
Abstract
The molecular signature of gain-of-function (GOF) vs. non-GOF classification TP53 mutations in colorectal cancer.Org: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, UAB O'Neal Comprehensive Cancer Center, Barbara Ann Karmanos Cancer Institute,
Abstract
Molecular characterization of nectin-4 in non-small cell lung cancer subtypes.Org: Caris Life Sciences Research and Development, Lombardi Comprehensive Cancer Center, Barbara Ann Karmanos Cancer Institute, Montefiore Einstein Center for Cancer Care, Caris Life Sciences, Irving, TX,